Hallucinogens are known to affect cognition, perception and emotions; we still, however, know little about how these drugs produce their mind-altering effects. Hallucinogenic action is thought to occur by binding and activating a subtype of serotonin receptor, called the 2A. In this edition of Dose of Science, we look at a recent paper which demonstrates the role of this receptor during psychedelic experiences.

A psychedelic renaissance is happening right now; but before classic hallucinogenic drugs can be accepted into mainstream medicine, their safety must be demonstrated. To move towards this goal, Norwegian scientists published a study claiming that psychedelics are not linked to long-term mental health problems; these findings, however, were quickly challenged. Dose of Science takes a look at the debate.

This movie is featuring the Global Ibogaine Conference that was held in Mexico in March, filmed by a member of Drugreporter’s new global video network and an alumni of our video advocacy training, Brun Balanced and his peers, Karina Muscarina and Gabriel Amezcua.

Every cannabis smoker knows that the major psychoactive ingredient of the plant is Δ9-tetrahydrocannabinol (THC), but there is also a range of other chemicals in marijuana smoke. One of the other significant components is cannabidiol (CBD). Anecdotal evidence suggests that CBD can inhibit some negative side effects associated with marijuana, but does this claim stand up to scientific scrutiny?

The research with psychedelic drugs can change our understanding of the human mind. Watch our video report from the International Interdisciplinary Conference on Psychedelic Research! Watch some of the key presentations too!

Leading national and international experts and activists discussed barriers and opportunities at the first conference on medical cannabis in Hungary.  

Medical cannabis activists formed an alliance with a political party, in order to contest the parliamentary elections in Serbia. Read Irena Molnar’s report from Belgrade, and watch the video!

A surprise decision from the otherwise super-conservative Polish government: it improves access to cannabis for medical purposes.

Progress should not cause us to lose sight of our core values. Please watch our video and read our article about the 2015 International Drug Policy Reform Conference, which was held in Washington DC between 18-21 November!

A speech delivered by the Director of the Drug Policy Alliance at the opening session of the International Drug Policy Reform Conference in Washington DC.